There are emerging data on the use of BRAF and mitogen-activated protein kinase kinase 1 inhibitors in LCH cases with proven BRAF mutations, with the majority having a complete remission throughout the duration of therapy.2 This evidence concerns the gene BRAF and Langerhans cell histiocytosis.